Inactivating hepatitis C virus in donor lungs using light therapies during normothermic ex vivo lung perfusion
Marcos Galasso, Jordan J Feld, Yui Watanabe, Mauricio Pipkin, Cara Summers, Aadil Ali, Robert Qaqish, Manyin Chen, Rafaela V P Ribeiro, Khaled Ramadan, Layla Pires, Vanderlei S Bagnato, Cristina Kurachi, Vera Cherepanov, Gray Moonen, Anajara Gazzalle, Thomas K Waddell, Mingyao Liu, Shaf Keshavjee, Brian C Wilson, Atul Humar, Marcelo Cypel, Marcos Galasso, Jordan J Feld, Yui Watanabe, Mauricio Pipkin, Cara Summers, Aadil Ali, Robert Qaqish, Manyin Chen, Rafaela V P Ribeiro, Khaled Ramadan, Layla Pires, Vanderlei S Bagnato, Cristina Kurachi, Vera Cherepanov, Gray Moonen, Anajara Gazzalle, Thomas K Waddell, Mingyao Liu, Shaf Keshavjee, Brian C Wilson, Atul Humar, Marcelo Cypel
Abstract
Availability of organs is a limiting factor for lung transplantation, leading to substantial mortality rates on the wait list. Use of organs from donors with transmissible viral infections, such as hepatitis C virus (HCV), would increase organ donation, but these organs are generally not offered for transplantation due to a high risk of transmission. Here, we develop a method for treatment of HCV-infected human donor lungs that prevents HCV transmission. Physical viral clearance in combination with germicidal light-based therapies during normothermic ex-vivo Lung Perfusion (EVLP), a method for assessment and treatment of injured donor lungs, inactivates HCV virus in a short period of time. Such treatment is shown to be safe using a large animal EVLP-to-lung transplantation model. This strategy of treating viral infection in a donor organ during preservation could significantly increase the availability of organs for transplantation and encourages further clinical development.
Conflict of interest statement
M.Cypel, T.W., S.K. and M.L. are founders of XOR Labs Toronto and M.Cypel, T.W. and S.K are consultants for Lung Bioengineering. J.J.F is consultant for AbbVie, Gilead Sciences, Merck and ContraVir. The remaining authors declare no competing interests.
Figures
References
- Cypel M, et al. Technique for prolonged normothermic ex vivo lung perfusion. J. Heart Lung. Transplant. 2008;27:1319–1325. doi: 10.1016/j.healun.2008.09.003.
- Valapour M, et al. OPTN/SRTR 2013 annual data report: lung. Am. J. Transplant. 2015;15:1–28. doi: 10.1111/ajt.13200.
- Cypel M, et al. Normothermic ex vivo lung perfusion in clinical lung transplantation. New Engl. J. Med. 2011;364:1431–1440. doi: 10.1056/NEJMoa1014597.
- Bennett D, et al. Mortality on the waiting list for lung transplantation in patients with idiopathic pulmonary fibrosis: a single-centre experience. Lung. 2015;193:677–681. doi: 10.1007/s00408-015-9767-x.
- Machuca TN, et al. Lung transplantation with donation after circulatory determination of death donors and the impact of ex vivo lung perfusion: DCDD lung transplantation and EVLP. Am. J. Transplant. 2015;15:993–1002. doi: 10.1111/ajt.13124.
- Inci I, et al. Ex vivo reconditioning of marginal donor lungs injured by acid aspiration. J. Heart Lung. Transplant. 2008;27:1229–1236. doi: 10.1016/j.healun.2008.07.027.
- Nakajima D, et al. Lung lavage and surfactant replacement during ex vivo lung perfusion for treatment of gastric acid aspiration–induced donor lung injury. J. Heart Lung. Transplant. 2017;36:577–585. doi: 10.1016/j.healun.2016.11.010.
- Machuca TN, et al. Injury-specific ex vivo treatment of the donor lung: pulmonary thrombolysis followed by successful lung transplantation. Am. J. Respir. Crit. Care. Med. 2013;188:878–880. doi: 10.1164/rccm.201302-0368LE.
- Ansaldi F. Hepatitis C virus in the new era: Perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy. World J. Gastroenterol. 2014;20:9633. doi: 10.3748/wjg.v20.i29.9633.
- Bajpai M, Gupta E, Choudhary A. Hepatitis C virus: screening, diagnosis, and interpretation of laboratory assays. Asian J. Transfus. Sci. 2014;8:19. doi: 10.4103/0973-6247.126683.
- Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin. Microbiol. Infect. 2011;17:107–115. doi: 10.1111/j.1469-0691.2010.03432.x.
- Fong T, et al. Outcomes after lung transplantation and practices of lung transplant programs in the united states regarding hepatitis c seropositive recipients. Transplantation. 2011;91:1293–1296. doi: 10.1097/TP.0b013e3182193cd3.
- Durand, C. M. et al. The drug overdose epidemic and deceased-donor transplantation in the united states: a national registry study. Ann. Internal Med. 168, 702–711 (2018).
- Tullius SG, Rabb H. Improving the supply and quality of deceased-donor organs for transplantation. New Engl. J. Med. 2018;378:1920–1929. doi: 10.1056/NEJMra1507080.
- Englum BR, et al. Impact of donor and recipient hepatitis C status in lung transplantation. J. Heart Lung. Transplant. 2016;35:228–235. doi: 10.1016/j.healun.2015.10.012.
- Cotler SJ, Jensen DM, Kesten S. Hepatitis C virus infection and lung transplantation: a survey of practices. J. Heart Lung. Transplant. 1999;18:456–459. doi: 10.1016/S1053-2498(98)00053-9.
- Reese PP, Abt PL, Blumberg EA, Goldberg DS. Transplanting Hepatitis C–positive kidneys. New Engl. J. Med. 2015;373:303–305. doi: 10.1056/NEJMp1505074.
- Cypel M, Keshavjee S. Extracorporeal lung perfusion (ex-vivo lung perfusion) Curr. Opin. Organ Transplant. 2016;21:329–335. doi: 10.1097/MOT.0000000000000320.
- A randomized trial of normothermic preservation in liver transplantation. Nature557, 50–56 (2018).
- Mohr H, et al. Blood components: a novel approach to pathogen reduction in platelet concentrates using short-wave ultraviolet light: UVC irradiation for pathogen reduction in PCs. Transfusion. 2009;49:2612–2624. doi: 10.1111/j.1537-2995.2009.02334.x.
- Dai T, Vrahas MS, Murray CK, Hamblin MR. Ultraviolet C irradiation: an alternative antimicrobial approach to localized infections? Expert Rev. Anti. Infect. Ther. 2012;10:185–195. doi: 10.1586/eri.11.166.
- Steinmann E, et al. Two pathogen reduction technologies-methylene blue plus light and shortwave ultraviolet light-effectively inactivate hepatitis C virus in blood products: inactivation of hcv in blood products. Transfusion. 2013;53:1010–1018. doi: 10.1111/j.1537-2995.2012.03858.x.
- Floyd RA, Schneider JE, Jr., Dittmer DP. Methylene blue photoinactivation of RNA viruses. Antivir. Res. 2004;61:141–151. doi: 10.1016/j.antiviral.2003.11.004.
- Müller-Breitkreutz K, Mohr H. Hepatitis C and human immunodeficiency virus RNA degradation by methylene blue/light treatment of human plasma. J. Med. Virol. 1998;56:239–245. doi: 10.1002/(SICI)1096-9071(199811)56:3<239::AID-JMV11>;2-9.
- Bachmann B, Knüver-Hopf J, Lambrecht B, Mohr H. Target structures for HIV-1 inactivation by methylene blue and light. J. Med. Virol. 1995;47:172–178. doi: 10.1002/jmv.1890470211.
- Khan B, et al. Successful lung transplantation from hepatitis c positive donor to seronegative recipient. Am. J. Transplant. 2017 doi: 10.1111/ajt.14137.
- Moutaoufik MT, et al. UVC-induced stress granules in mammalian cells. PLoS. One. 2014;9:e112742. doi: 10.1371/journal.pone.0112742.
- Smith DB, et al. Variation of the hepatitis C virus 5′ non-coding region: implications for secondary structure, virus detection and typing. J. General. Virol. 1995;76:1749–1761. doi: 10.1099/0022-1317-76-7-1749.
- Dai T, Vrahas MS, Murray CK, Hamblin MR. Ultraviolet C irradiation: an alternative antimicrobial approach to localized infections? Expert. Rev. Anti. Infect. Ther. 2012;10:185–195. doi: 10.1586/eri.11.166.
- Wakita, T. in Hepatitis C: Methods and Protocols Vol. 510, 2nd edn (ed. Tang, E.) 305–327 (Humana Press, 2009).
- Lindenbach BD, et al. Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro. PNAS. 2006;103:3805–3809. doi: 10.1073/pnas.0511218103.
- Pietschmann T, et al. Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. PNAS. 2006;103:7408–7413. doi: 10.1073/pnas.0504877103.
- Mariscal A, et al. Pig lung transplant survival model. Nat. Protoc. 2018;13:1814–1828. doi: 10.1038/s41596-018-0019-4.
- Maverakis E, et al. Light, Including Ultraviolet. J. Autoimmun. 2010;34:J247–J257. doi: 10.1016/j.jaut.2009.11.011.
- Feld JJ, et al. Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. New Engl. J. Med. 2015;373:2599–2607. doi: 10.1056/NEJMoa1512610.
- Helfritz, F. A. et al. Methylene blue treatment of grafts during cold ischemia time reduces the risk of hepatitis c virus transmission. J. Infect. Dis. 218, 1711–1721 (2018).
- Machuca TN, Cypel M. Ex vivo lung perfusion. J. Thorac. Dis. 2014;6:1054–1062.
- Cypel M, et al. Experience with the first 50 ex vivo lung perfusions in clinical transplantation. J. Thorac. Cardiovasc. Surg. 2012;144:1200–1207. doi: 10.1016/j.jtcvs.2012.08.009.
- Sundaresan S, Trachiotis GD, Aoe M, Patterson GA, Cooper JD. Donor lung procurement: Assessment and operative technique. Ann. Thorac. Surg. 1993;56:1409–1413. doi: 10.1016/0003-4975(93)90699-I.
- Franken NAP, Rodermond HM, Stap J, Haveman J, van Bree C. Clonogenic assay of cells in vitro. Nat. Protoc. 2006;1:2315–2319. doi: 10.1038/nprot.2006.339.
Source: PubMed